REL-1017

· Relmada Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for REL-1017, covering 2021-03-17 to 2026-07-10. Get the full timeline:

Most recent: Clinical Trial Results: A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) [Phase 3]

See pricing